14th Congress of the EMGM, European Meningococcal and Haemophilus Disease Society
September 18–21, 2017
Prague, Czech Republic

FINAL PROGRAMME
TABLE OF CONTENTS

WELCOME MESSAGE .......................... 4
SCIENTIFIC COMMITTEE .................. 5
CONGRESS SECRETARIAT .................. 5
PROGRAMME OVERVIEW .................. 6
PROGRAMME IN DETAIL .................. 7
SATELLITE SYMPOSIA ..................... 16
EMGM GENERAL ASSEMBLY .............. 16
POSTERS .................................... 17
ABSTRACTS .................................. 22
REGISTRATION ................................ 22
SPEAKERS’ READY DESK ................. 23
SOCIAL EVENTS ............................ 24
GENERAL INFORMATION ................. 25
MAP OF THE VENUE ....................... 26

ACKNOWLEDGEMENTS

Platinum Partner

Pfizer

Gold Partner

gsk

Bronze Partners
WELCOME MESSAGE

Welcome to the 14th conference of the EMGM held in the beautiful city of Prague. We invited our members and everyone who is interested in public health microbiology and epidemiology of invasive meningococcal and *Haemophilus influenzae* disease to share with us exciting days of scientific exchange and discussion. The field is developing with new techniques of strain characterization, new vaccines, new approaches to public health management, and ever changing epidemiological developments. We sincerely hope that the conference will be the start of various European collaborations in the frame of the EMGM society. It is a major goal to attract young scientists to the topic and travel grants will be provided to pursue this aim. We are happy to meeting you in Prague to join the bi-annual meeting of the EMGM Society.

We thank to all who made the meeting possible, including the members of Scientific Committee, who reviewed the abstracts and selected oral presentations. We thanks as well to all who agreed to chair the Oral sessions and the Workshops. Finally, we thank to the sponsors for their financial support.

Ulrich Vogel  
President of the EMGM Society

Pavla Krizova  
Congress Chair

SCIENTIFIC COMMITTEE

Ray Borrow  
Arie van der Ende  
Ian Feavers  
Jamie Findlow  
Steve Gray  
Germaine Hanquet  
Wiebke Hellenbrand  
Pavla Krizova  
Shamez Ladhani  
Thiên-Trí Lâm  
Martin Maiden  
Paola Stefanelli  
Muhamed-Kheir Taha  
Caroline Trotter  
Georgina Tzanakaki  
Julio Vázquez  
Ulrich Vogel

CONGRESS SECRETARIAT

GUARANT International  
Na Pankráci 17  
140 21 Prague 4  
Czech Republic  
Phone: +420 284 001 444  
Fax: +420 284 001 448  
E-mail: emgm2017@guarant.cz
PROGRAMME OVERVIEW

**Monday September 18, 2017**
- 16:00–18:00: Registration
- 18:00–21:00: Welcome session

**Tuesday September 19, 2017**
- 08:00–16:30: Registration
- 08:30–09:00: Welcome address
- 09:00–10:15: Oral session 1
- 10:15–10:45: Coffee break
- 10:45–12:15: Oral session 2
- 12:15–13:30: Lunch break and poster viewing
- 13:30–14:00: Oral session 3
- 14:00–15:15: Pfizer Satellite symposium
- 15:15–16:45: Coffee break and poster viewing
- 16:45–18:00: Oral session 4
- 19:00: EMGM General assembly

**Wednesday September 20, 2017**
- 08:00–09:15: Oral session 5
- 09:15–10:15: Coffee break
- 10:15–12:15: Workshop 1
- 12:15–13:15: Lunch break
- 13:15–14:30: Workshop 2
- 14:30–15:15: Coffee break
- 15:15–16:35: Oral session 6
- 16:35–17:30: Poster viewing
- 17:30–18:00: GSK Satellite symposium
- 18:45: Departure for Dinner
- 19:30–21:30: Gala dinner

**Thursday September 21, 2017**
- 08:00–14:00: Registration
- 08:30–09:45: Workshop 3
- 09:45–10:15: Coffee break
- 10:15–12:15: Workshop 4
- 12:15–13:15: Lunch break
- 13:15–14:15: Oral session 7
- 14:15: Closing session

PROGRAMME IN DETAIL

**Monday 18 September**
- **16:00–18:00**: Arrival and registration

**18:00–21:00**: Welcome session
- 18:00–19:00: Welcome reception
- 19:00–19:30: ECDC strategy and implementation plan for sequence-based molecular typing of invasive meningococcal disease at the EU level
  - **Karin Johansson**, ECDC, Sweden
- 19:30–20:00: Recent changes in meningococcal epidemiology in Australia and implementation of a population study to investigate the impact of MenB vaccination on meningococcal carriage in South Australian adolescents
  - **Helen Marshall**, Adelaide, Australia
- 20:00–20:30: Discussion
- 20:30–21:00: Informal gathering continued
## Tuesday 19 September

### 08:00-16:30 Registration

### 08:30-09:00 Welcome address
- Ulrich Vogel, EMGM President
- Pavla Krizova, EMGM 2017 Chair
- Sam Rosoman, CoMO Executive Director

### 09:00-10:15 Oral session 1: Epidemiology of invasive meningococcal and *Haemophilus influenzae* disease
**Moderators:** Martin Maiden & Paula Mölling

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author</th>
<th>Place</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:15</td>
<td>Whole genome sequencing of the emerging invasive <em>Neisseria meningitidis</em> serogroup W in Sweden</td>
<td>Lorraine Eriksson, Örebro, Sweden</td>
<td></td>
</tr>
<tr>
<td>09:15-09:30</td>
<td>Development of EMERT II – European Meningococcal Epidemiology in Real Time: the genomic era</td>
<td>Keith A Jolley, Oxford, UK</td>
<td></td>
</tr>
<tr>
<td>09:30-09:45</td>
<td>Abdominal presentation of invasive meningococcal infections: an underestimated diagnosis</td>
<td>Tamazoust Guiddir, Paris, France</td>
<td></td>
</tr>
<tr>
<td>09:45-10:00</td>
<td>Meningococcal B vaccination and its possible implementation into national immunization calendar in the Czech Republic</td>
<td>Roman Prymula, Hradec Králové, Czech Republic</td>
<td></td>
</tr>
<tr>
<td>10:00-10:15</td>
<td>Long-term mortality after invasive NTHi infection</td>
<td>Sarah Collins, London, UK</td>
<td></td>
</tr>
</tbody>
</table>

### 10:15-10:45 Coffee break

### 10:45-12:15 Oral session 2: Strain characterization and antibiotic resistance of *Neisseria meningitidis* and *Haemophilus influenzae*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author</th>
<th>Place</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45-11:00</td>
<td>Fifteen years of antimicrobial susceptibility surveillance of invasive meningococcal isolates in Germany</td>
<td>Heike Claus, Würzburg, Germany</td>
<td></td>
</tr>
<tr>
<td>11:00-11:15</td>
<td>Characterisation of meningococcal isolates responsible for invasive meningococcal disease in patients with terminal complement pathway deficiencies</td>
<td>Muhamed-Kheir Taha, Paris, France</td>
<td></td>
</tr>
</tbody>
</table>

### 11:15-11:30 Emergence of meningococci with reduced susceptibility to third-generation cephalosporins
- **Ala-Eddine Deghmane,** Paris, France

### 11:30-11:45 Invasive meningococcal disease: clinical and microbiological analysis
- **Olga Dzupova,** Prague, Czech Republic

### 11:45-12:00 Development of Bexsero® outer membrane vesicle typing system for analysis of meningococcal whole genome sequences
- **Charlene Rodrigues,** Oxford, UK

### 12:00-12:15 Imipenem susceptibility in invasive *H. influenzae* isolates in Germany 2016
- **Thien-Tri Lam,** Würzburg, Germany

### 12:15-13:30 Lunch break and poster viewing

### 13:30-14:00 Oral session 3: Public Health Management

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author</th>
<th>Place</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-13:45</td>
<td>Revised Guidance for the Evaluation and Public Health Management of Suspected Outbreaks of Meningococcal Disease in the United States</td>
<td>Sarah A Meyer, Atlanta, USA</td>
<td></td>
</tr>
<tr>
<td>13:45-14:00</td>
<td>Pre-hospital antibiotics in meningococcal disease: Methods for robust analysis of surveillance data to guide public health management</td>
<td>Amanda Kvalsvig, Wellington, New Zealand</td>
<td></td>
</tr>
</tbody>
</table>

### 14:00-15:15 Pfizer Satellite symposium: Helping prevent MenB by targeting FHbp, a meningococcal protein critical to immune evasion
**Chair:** Paul Balmer

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author</th>
<th>Place</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:05</td>
<td>Welcome &amp; Introduction</td>
<td>Paul Balmer, Pfizer Vaccines</td>
<td></td>
</tr>
<tr>
<td>14:05-14:35</td>
<td>Role of the polysaccharide capsule and factor H binding protein in protecting <em>Neisseria meningitidis</em> from the immune system</td>
<td>Jamie Findlow, Pfizer Vaccines</td>
<td></td>
</tr>
<tr>
<td>14:35-15:05</td>
<td>Trumenba: vaccine development, mechanism of action and clinical data of a bivalent factor H binding protein vaccine</td>
<td>Bernard Fritzel, BFL Consulting</td>
<td></td>
</tr>
<tr>
<td>15:05-15:15</td>
<td>Q&amp;A and Concluding Remarks</td>
<td>Paul Balmer, Pfizer Vaccines</td>
<td></td>
</tr>
</tbody>
</table>

### 15:15-16:45 Coffee break and poster viewing
16:45–18:00 Oral session 4: Laboratory surveillance by molecular techniques of invasive meningococcal and Haemophilus influenzae disease Moderators: Thien-Tri Lam & Ala-Eddine Deghmane

16:45–17:00 Invasive Neisseria meningitidis Population Structure Ten Years After Recommended Use of the Quadrivalent Meningococcal Conjugate Vaccine in the United States Caelin Potts, Atlanta, USA


17:15–17:30 Targeted DNA enrichment and whole genome sequencing of Neisseria meningitidis directly from clinical specimens Stephen A Clark, Manchester, UK

17:30–17:45 Evaluation of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry in identifying Neisseria species Eva Hong, Paris, France

17:45–18:00 Capsule loss in invasive Haemophilus influenzae serotype b. Kenneth Meyler, Dublin, Ireland

19:00 EMGM General assembly

Wednesday 20 September

08:00–16:30 Registration

08:30–09:15 Oral session 5: Carriage dynamics in meningococci and Haemophilus influenzae Moderators: Georgina Tzanakaki & Robert Mulhall

08:30–08:45 Risk Factors for Carriage of Neisseria meningitidis in British Teenagers associated with changing disease incidence Jenny M. MacLennan, Oxford, UK

08:45–09:00 Whole genome sequencing reveals within-host genetic changes in paired meningococcal carriage isolates from Ethiopia Guro K Bårnes, Oslo, Norway

09:00–09:15 Capsule genes are common among Neisseria commensals Marianne Clemence, Oxford, UK

09:15–10:15 Coffee break

10:15–12:15 Workshop 1: Increased incidence of invasive meningococcal disease due to serogroup W in Europe and Chile: Epidemiology, genomic analysis and impact of MenACWY vaccines Conveners: Wiebke Hellenbrand & Shamez Ladhani

10:15–10:20 Brief overview of MenWCY epidemiology and vaccination recommendations in European countries Wiebke Hellenbrand, Berlin, Germany

10:20–10:35 Increase in invasive serogroup W meningococcal disease since 2015 in the Netherlands Mirjam J Knol, Bilthoven, the Netherlands

10:35–10:45 Clonal replacement and expansion within invasive isolates of serogroup W in France Anne-Sophie Barret, Saint Maurice, France

10:45–10:55 Increase of serogroup W meningococcal invasive strains in Spain: Genomic analysis Julio A. Vazquez, Majadahonda, Spain

10:55–11:05 Laboratory surveillance of serogroup W meningococcal disease in Germany Helke Claus, Würzburg, Germany

11:05–11:20 Chilean experience with serogroup W outbreak and meningococcal ACWY conjugate vaccines Rodolfo Villena, Santiago, Chile
11:20–11:40 Increased incidence of serogroup W IMD in England and impact of MenACWY vaccination programme in adolescents
Helen Campbell, London, UK

11:40–12:15 Panel discussion: Implications of the MenW increase for meningococcal vaccination strategies in European countries

12:15–13:15 Lunch break

13:15–14:30 Workshop 2: Meningococcal disease and complement deficiency
Conveners: Ian Feavers & Ray Borrow
13:15–13:35 The action of Eculizumab and experience of managing patients on this therapy
Alexander Rüth, Essen, Germany
13:35–13:55 Immune responses to meningococcal vaccination in patients on Eculizumab therapy
Stephen Hughes, Manchester, UK
13:55–14:15 The genetic basis of different late complement component deficiencies patients and the genetic characteristics of their invasive meningococcal strains
Muhammed-Kheir Taha, Paris, France
14:15–14:30 Feedback from the EMGM complement deficiency questionnaire
Ray Borrow, Manchester, UK

14:30–15:15 Coffee break

15:15–16:30 Oral session 6: Vaccine implementation and new vaccines 1
Moderators: Julio Vazquez & Anna Skoczynska
15:15–15:30 Enhanced surveillance of invasive meningococcal disease following introduction of 4CMenB (Bexsero) into the UK infant vaccination schedule; what can the laboratory data tell us?
Jay Lucidarme, Manchester, UK
15:30–15:45 A global assessment of Bexsero strain coverage: comparative analysis of MATS and antigen genotyping
Alessandro Muzzi, Siena, Italy
15:45–16:00 Trumenba® Elicits Bactericidal Antibodies Against Non-Serogroup B Meningococci
Thomas R Jones, Pearl River, USA

16:00–16:20 A Bivalent Meningococcal B Vaccine Elicits Robust Bactericidal Responses in Adolescents and Young Adults against Diverse Meningococcal B Strains / Persistence and 4-Year Boosting of the Bactericidal Response Elicited by 2- and 3-Dose Schedules of MenB-FHbp
Johannes Beeslaar, Hurley, UK

16:20–16:35 Vaccine effectiveness against Haemophilus influenzae serotype b disease following introduction of Hepatitis B containing vaccine in the Netherlands
Mirjam J Knol, Bilthoven, the Netherlands
Thursday 21 September

08:00–14:00 Registration

08:30–09:45 Workshop 3: Atypical manifestations of meningococcal and Haemophilus influenzae disease

**Convener:** Muhamed-Kheir Taha

08:30–08:35 Introduction

**Muhamed-Kheir Taha,** Paris, France

08:35–09:20 Short communications from the reference centres (Nm and Hi) in selected European countries

**Heads of selected reference centres (Nm and Hi)**

09:20–09:35 A global discussion

09:35–09:45 A short conclusion

**Muhamed-Kheir Taha,** Paris, France

09:45–10:15 Coffee break

10:15–12:15 Workshop 4: Experience with MenB vaccination: Update on vaccine effectiveness and impact, safety, vaccination strategies and future outlook

**Conveners:** Shamez Ladhani & Wiebke Hellenbrand

10:15–10:20 Brief overview of MenB epidemiology and vaccination recommendations in European countries

**Wiebke Hellenbrand,** Berlin, Germany

10:20–10:35 Update on effectiveness and impact of Bexsero vaccination in infants in England

**Sydel R Parikh,** London, UK

10:35–11:05 Update on Safety of Bexsero:

10:35–10:50 Active and passive postmarketing surveillance “Bexsero (4CMenB) vaccine – the UK safety experience”

**Philip Bryan,** London, UK

10:50–11:05 Presentation to ED, primary care and hospitals after Bexsero vaccination

**Shamez Ladhani,** London, UK

11:05–11:35 Experience with MenB vaccination in other countries:

11:05–11:20 The developments in the epidemiological situation of invasive meningococcal diseases in the West Bohemian region and the current options for vaccination

**Petr Pazdiora,** Pilsen, Czech Republic

11:20–11:35 Implementation of MenB vaccination in Italy

**Paola Stefanelli,** Rome, Italy

11:35–11:50 Comparative overview of Trumenba® and Bexsero®: Composition, strain coverage, immunogenicity, potential herd protection, safety and impact in adolescents and adults

**Wiebke Hellenbrand,** Berlin, Germany

11:50–12:15 Panel Discussion: Outlook for MenB vaccination

12:15–13:15 Lunch break

13:15–14:15 Oral session 7: Vaccine implementation and new vaccines 2

**Moderators:** Susanne Jacobsson & Jay Lucidarme

13:15–13:30 Impact of Meningococcal C vaccination in Germany

**Wiebke Hellenbrand,** Berlin, Germany


**Giovanni Rezza,** Roma, Italy

13:45–14:00 Immune Persistence of MenA specific antibody in Ghanaian children more than five years after immunization with PsA-TT (2.5 µg, 5 µg, or 10 µg polysaccharide concentration)

**Patrick O Ansah,** Navrongo, Ghana

14:00–14:15 MenAfriVac Immunogenicity and Micronutrient Status among Malian Children

**Maria E Sundaram,** Minneapolis, USA

14:15 Closing session

Presentation of venue for EMGM 2019

**Paola Stefanelli,** EMGM Vice-President
SATELLITE SYMPOSIA

**Pfizer**
*Helping prevent MenB by targeting FHbp, a meningococcal protein critical to immune evasion*
**Tuesday, September 19, 2017, 14:00–15:15**
- Welcome & Introduction – Paul Balmer
- Role of the polysaccharide capsule and factor H binding protein in protecting Neisseria meningitidis from the immune system – Jamie Findlow
- Trumenba: vaccine development, mechanism of action and clinical data of a bivalent factor H binding protein vaccine – Bernard Fritzell
- Q&A and Concluding Remarks – Paul Balmer

**GSK**
*Development and international use of 4CMenB*
**Wednesday, September 20, 2017, 17:30–18:00**
- Development and introduction of 4CMenB – Angelika Banzhoff
- Use of 4CMenB in Saguenay-Lac St. Jean, a region of Quebec, Canada – Veronique Abitbol
- Q&A – Angelika Banzhoff

EMGM GENERAL ASSEMBLY

**Wednesday, September 20, 2017, 19:00**

POSTERS

**The Poster Area is located in the conference room Prague D.**

**Poster Session Timing**
Authors are invited to put up their posters as early as possible starting from Monday, September 18, 14:00. The poster sessions will be officially open on Monday, September 18 from 18:00.

In order to enable discussion and interaction with other participants, we kindly request the main author or another member of the group to be at the poster board during the scheduled poster-viewing sessions. If it is not possible, we kindly ask the authors to leave a note on the poster indicating times when they will be present at the board.

Posters will be displayed until Thursday, September 21, 15:00. We kindly ask the presenters to remove the posters preferably before 15:00 otherwise the posters will be removed and discarded.

**LIST OF POSTERS**

**Epidemiology of invasive meningococcal, pneumococcal and Haemophilus influenzae disease**

**P01 Invasive Diseases due to Neisseria meningitidis and Haemophilus Influenzae in Italy, 2015–2016**
*Paola Stefanelli*, Rome, Italy

**P02 Invasive meningococcal disease in Poland, 2015–2016**
*Izabela Waśko*, Warsaw, Poland

**P03 Distribution of Neisseria meningitidis sequence types in CIS countries**
*Yulia Urban*, Moscow, Russian Federation

**P04 The epidemiology of invasive meningococcal disease and vaccination strategy in the Czech Republic**
*Pavla Krizu*, Prague, Czech Republic

**P05 Epidemiology of meningococcal disease in Germany**
*Wiebke Hellenbrand*, Berlin, Germany

**P06 Epidemiology of invasive meningococcal disease in Finland, 2016**
*Maija Toropainen*, Helsinki, Finland

**P07 Why should teenagers and adults in the UK consider protecting themselves against meningococcal serogroup B disease?**
*Andrew Vyse*, Tadworth, Walton Oaks, UK

**P08 Invasive meningococcal disease in Sweden 2016**
*Susanne Jacobsson*, Örebro, Sweden

**P09 Invasive meningococcal disease in the Netherlands, 2015–2016**
*Arie van der Ende*, Amsterdam, the Netherlands
<table>
<thead>
<tr>
<th>Paper Nr.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P10</td>
<td>Meningococcal disease in the Middle East and Africa: Findings and updates from the Global Meningococcal Initiative</td>
<td>Ener Cagri Dinleyici, Eskisehir, Turkey</td>
</tr>
<tr>
<td>P11</td>
<td>Epidemiology of two decades of invasive meningococcal disease in the Republic of Ireland: an analysis of national surveillance data</td>
<td>Robert Mulhall, Dublin, Ireland</td>
</tr>
<tr>
<td>P12</td>
<td>Epidemiology of Invasive Meningococcal Disease in the Republic of Ireland during the epidemiological year 2015/2016</td>
<td>Robert Mulhall, Dublin, Ireland</td>
</tr>
<tr>
<td>P13</td>
<td>Epidemiology and surveillance of meningococcal disease in England</td>
<td>Steve Gray, Manchester, UK</td>
</tr>
<tr>
<td>P14</td>
<td>Invasive disease caused by Neisseria meningitidis, Croatia January 2015 – May 2017</td>
<td>Suzana Bukovski, Zagreb, Croatia</td>
</tr>
<tr>
<td>P15</td>
<td>National increase in meningococcal group C disease, Scotland, 2016</td>
<td>Kevin Scott, Glasgow, UK</td>
</tr>
<tr>
<td>P16</td>
<td>Establishment of the Meningitis Research Foundation Meningococcus Genome Library as a keystone of global meningococcal research</td>
<td>Jay Lucidarme, Manchester, UK</td>
</tr>
<tr>
<td>P17</td>
<td>Invasive meningococcal disease in Greece: 2 year epidemiological data (2015–2016)</td>
<td>Konstantinos Kesanovaopoulos, Athens, Greece</td>
</tr>
<tr>
<td>P18</td>
<td>Epidemiology of invasive meningococcal disease in Portugal in the last decade – 2007–2016</td>
<td>Maria João Simões, Lisbon, Portugal</td>
</tr>
<tr>
<td>P19</td>
<td>Epidemiology of invasive meningococcal disease in university students in England</td>
<td>Sonia Ribeiro, London, UK</td>
</tr>
<tr>
<td>P20</td>
<td>Invasive Haemophilus influenzae disease in the Czech Republic in 1999–2016</td>
<td>Vera Lebedova, Prague, Czech Republic</td>
</tr>
<tr>
<td>P21</td>
<td>Epidemiology of Haemophilus influenzae invasive disease in Portugal, 2011–2016</td>
<td>Catarina Heliodoro, Lisbon, Portugal</td>
</tr>
<tr>
<td>P22</td>
<td>Epidemiology of invasive Haemophilus influenzae disease in Finland, 2016</td>
<td>Maija Toropainen, Helsinki, Finland</td>
</tr>
<tr>
<td>P23</td>
<td>Invasive H. influenzae isolates from infants in Germany 2009–2016: laboratory surveillance report</td>
<td>Thien-Tri Lam, Würzburg, Germany</td>
</tr>
<tr>
<td>P24</td>
<td>Invasive Haemophilus influenzae population in Poland, 1997–2017</td>
<td>Alicja Kuch, Warsaw, Poland</td>
</tr>
<tr>
<td>P25</td>
<td>Invasive Haemophilus influenzae disease in the Netherlands, 2015–2016</td>
<td>Arie van der Ende, Amsterdam, the Netherlands</td>
</tr>
<tr>
<td>P26</td>
<td>Croatia – Invasive disease caused by Haemophilus influenzae, January 2015 – May 2017</td>
<td>Suzana Bukovski, Zagreb, Croatia</td>
</tr>
<tr>
<td>P27</td>
<td>Haemophilus influenzae Surveillance &amp; Epidemiology in Scotland 2016</td>
<td>Kevin Scott, Glasgow, UK</td>
</tr>
<tr>
<td>P29</td>
<td>Emergence of Invasive Haemophilus influenzae serotype a (Hia) disease in England</td>
<td>Sarah Collins, London, UK</td>
</tr>
<tr>
<td>P30</td>
<td>Invasive H. influenzae disease in England 15 years after the introduction of the a child Hib vaccine booster</td>
<td>David Litt, London, UK</td>
</tr>
<tr>
<td>P31</td>
<td>Invasive pneumococcal disease before implementation of population-based vaccination in Poland</td>
<td>Anna Skoczynska, Warsaw, Poland</td>
</tr>
<tr>
<td>P32</td>
<td>Invasive pneumococcal disease in the Czech Republic in 2016</td>
<td>Jana Kozáková, Prague, Czech Republic</td>
</tr>
<tr>
<td>P34</td>
<td>Rising incidence of Meningococcal serogroup W disease in Europe 2013–2016</td>
<td>Manuel Krone, Würzburg, Germany</td>
</tr>
<tr>
<td>P35</td>
<td>Invasive Meningococcal Disease: surveillance in Casablanca (Morocco)</td>
<td>Aziza Razki, Casablanca, Morocco</td>
</tr>
<tr>
<td>P36</td>
<td>Invasive Meningococcal Disease in Russian Federation</td>
<td>Irina Korableva, Moscow, Russian Federation</td>
</tr>
<tr>
<td>P37</td>
<td>Meningococcal disease in eculizumab recipients — United States, 2007–2016</td>
<td>Lucy McNamara, Atlanta, GA, United States</td>
</tr>
<tr>
<td>P38</td>
<td>Three Musketeers: Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae and Invasive Bacterial Disease – Croatia 2015–2016</td>
<td>Suzana Bukovski, Zagreb, Croatia</td>
</tr>
<tr>
<td>P39</td>
<td>The epidemiology of meningococcal disease in New Zealand 2015–2016</td>
<td>Heather Davies, Porirua, New Zealand</td>
</tr>
<tr>
<td>P40</td>
<td>Molecular characterization of serogroup B meningococci responsible for IMD in Poland in 2015</td>
<td>Izabela Wasa, Warsaw, Poland</td>
</tr>
<tr>
<td>P41</td>
<td>Genomic epidemiology of invasive ET-5 (ST-32cc) Neisseria meningitidis serogroup B isolates in Finland in 1995</td>
<td>Anni Vainio, Helsinki, Finland</td>
</tr>
<tr>
<td>P42</td>
<td>Phenotypic characteristics, susceptibility to antimicrobial drugs and molecular characterization of Meningococcus and Haemophilus invasive isolates in Serbia in a seven year period (2009–2016)</td>
<td>Davor Culic, Sombor, Serbia</td>
</tr>
</tbody>
</table>
**P43** Whole-genome-based characterization of invasive *Haemophilus influenzae* isolates from a pre- and post-vaccine era in Portugal
*Maria Paula Bajanca-Lavado*, Lisbon, Portugal

**Laboratory surveillance by molecular techniques of invasive meningococcal and Haemophilus influenzae disease**

**P44** Molecular surveillance of invasive meningococcal disease in the Czech Republic 2016
*Zuzana Vacková*, Praha 10, Czech Republic

**P45** Whole-genome sequencing (WGS) of *Neisseria meningitidis* and its potential for use in molecular surveillance of invasive meningococcal disease in the Czech Republic
*Michal Honskus*, Prague, Czech Republic

**P46** Invasive meningococcal diseases and aspect of nasofaryngeal state carrier in Slovakia in a year 2015 and 2016
*Anna Kruzliková*, Bratislava, Slovakia

**Vaccine implementation and new vaccines**

**P47** Clonal and antigen gene analysis of MenB vaccine components in invasive *Neisseria meningitidis* isolates from the Czech Republic, 2007–2016
*Martin Musílek*, Prague, Czech Republic

**P48** Evaluation of coverage of 4CMenB vaccine when administered to infants with different immunization schedules
*Alessia Biolchi*, Siena, Italy

**P49** Investigation of lipoproteins translocation system in *Neisseria meningitidis*
*Maria Giuliani*, Siena, Italy

**P50** Genetic variability of serogroup B carrier isolates in Greece in the pre- and post-Bexsero® vaccination era
*Konstantinos Kesanopoulos*, Athens, Greece

**P51** Use of saliva to monitor meningococcal vaccine responses: proposing a threshold as surrogate of protection
*Guy Berbers*, Bilthoven, the Netherlands

**P52** Meningococcal strain coverage in the Republic of Ireland in 3 years preceding the introduction of 4CMenB (Bexsero®) into the national infant immunization schedule
*Robert Mulhall*, Dublin, Ireland

**P53** Sustained increase in Accident and Emergency presentations for vaccine reactions in second year post-introduction of the meningococcal B vaccine: an observational study
*Neda So*, Oxford, UK & Clayton, Australia

**Carriage dynamics in meningococci and Haemophilus influenzae**

**P54** Meningococcal carriage by age in the African meningitis belt: a systematic review and meta-analysis
*Laura Cooper*, Cambridge, UK

**P55** Nasopharyngeal meningococcal carriage rate and serogroup distribution of Turkish citizens lived in Belgium, Germany and the Netherlands during their visit to Turkey
*Ener Cagri Dinleyici*, Eskisehir, Turkey

**P56** Genotypic and phenotypic characterization of the O-linked protein glycosylation system show high glycan diversity in paired meningococcal carriage isolates
*Bente Berud*, Oslo, Norway

**P57** Direct multiplexed digital detection of *Neisseria meningitidis* gene transcripts from culture and in vivo pharyngeal samples
*Yenenesh Tekletsion*, Bristol, UK

**P58** Pharyngeal carriage of *Neisseria meningitidis* among undergraduate students of Ahmadu Bello University, Zaria
*Shamsudin Aliyu*, Zaria, Nigeria
Name Badge

Participants will receive a name badge upon registration and are requested to wear this badge at all times during the Congress, including lunches and coffee breaks. The replacement of lost or forgotten badges carries a 30 EUR charge.

Registration Fee Includes

- Admission to the Opening Session
- Admission to the Conference Scientific Sessions
- Admission to the Poster Area
- Coffee Breaks and Light Lunches
- Conference Materials
- Abstracts [electronic version] on websites indicated above
- VAT

Registration Desk
The Registration Desk is located on the first floor of the Vienna House Diplomat Prague hotel – Foyer Prague.

The Registration Desk will be open as follows:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, September 18</td>
<td>16:00–18:00</td>
</tr>
<tr>
<td>Tuesday, September 19</td>
<td>08:00–16:30</td>
</tr>
<tr>
<td>Wednesday, September 20</td>
<td>08:00–16:30</td>
</tr>
<tr>
<td>Thursday, September 21</td>
<td>08:00–14:00</td>
</tr>
</tbody>
</table>

Certificate of Attendance
Certificates of Attendance will be distributed via email after the Congress.

Speakers’ Ready Desk
Please come to the Meeting Room of your presentation (Room Prague A + B + C) at least 1 ½ hour before the beginning of your session. In case your speech has been scheduled for morning session please come one day before the day of your presentation.

Timing of the Presentations
Please keep timing for your presentation in Oral Sessions and Workshops according to the Programme, where timing is indicated including the discussion to your presentation. There will be a timer for keeping your time. This equipment will be well seen at the preview display and the time will be also controlled by the chair of the sessions and workshops.
SOCIAL EVENTS

Gala Dinner

**Boat Cruise with Dinner**

- **Date:** September 20, 2017
- **Time:** 19:30–21:30
- **Location:** Dvořáková nábřeží, pier n. 15
- **Price:** 50 EUR
- **Organised departure:** 18:45 Vienna House Diplomat Prague

A cruise is truly one of the most delightful ways to see the beauties on offer in the historical centre of Prague. You can enjoy Prague’s historic sites while avoiding the busy streets from the utter peace and serenity of the river. Dinner on board in the middle of enchanting Prague guarantees perfect evening with your friends and colleagues.

Transportation to the pier will be provided by bus from the hotel Vienna House Diplomat Prague. **Departure is at 18:45 sharp from the hotel Diplomat. Please come ahead of time.**

The tickets can be purchased at the Registration Desk.

GENERAL INFORMATION

**Congress Venue**

Vienna House Diplomat Prague****
Evropská 15, 160 41 Prague 6
Web: www.viennahouse.com/en/diplomat-prague

**WiFi**

WiFi will be available in the exhibition foyer.
Username: Diplomat By Vienna House

**Public Transport**

Prague has a very sophisticated subway, tram and bus transport system. The Prague underground is quite new and efficient. At peak times, trains run every 2 or 3 minutes, and during off-peak hours at least every 8–10 minutes. You can find more information about Prague public transport on the web pages: http://www.dpp.cz/en/

24-hour pass **110 CZK / 4.20 EUR** 3-day pass (72 hours) **310 CZK / 11.60 EUR**

**Taxi Service**

We recommend you use following taxi companies:
Profi Taxi: +420 261 314 151 or +420 844 700 800
AAA Taxi: +420 222 333 222 or +420 2211 0 2211

**Insurance**

The organizers can accept no liability for personal injuries or for loss or damage to property belonging to the meeting participants, either during or as a result of the event. Participants are advised to take out proper travel and health insurance before departing from their home country.

**Currency and Exchange Rates**

Czech crown (CZK) is the official currency of the Czech Republic. Exchange of foreign currency is available at Prague international Airport and at most hotels, banks and exchange offices throughout the city. International credit cards are accepted for payments in hotels, restaurants and shops. Payment in cash in EUR is also available in some restaurants and shops, please ask for details on-site. You can find the official exchange rates on the website of the Czech National Bank at www.cnb.cz.

**Important Telephone Numbers**

112: General Emergency for Europe
150: Fire
155: Ambulance
158: Police